Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Allergan’s Ganfort receives expanded European approval

Allergan’s Ganfort receives expanded European approval

9th September 2013

Allergan has had the European marketing authorisation for its ophthalmic solution Ganfort extended to include a new formulation.

A preservative-free formulation of the drug will be made available in single-dose containers across all 27 EU countries, reaching the UK midway through September 2013.

It will be the first preservative-free prostaglandin fixed combination glaucoma treatment to be made available in Europe, providing a useful new therapy option for patients who are sensitive or intolerant to preservatives.

Ganfort is licensed for the reduction of intraocular pressure among patients with open-angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

Martin Gillen, country manager for the UK and Ireland at Allergan, said: "This new formulation provides a meaningful addition to our already well-established portfolio of effective glaucoma treatments."

Allergan employs around 11,100 workers worldwide and has a commercial presence in more than 100 countries.ADNFCR-8000103-ID-801634966-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.